Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.2652W HIGH $6.87
Volume
88.04 K
Value Traded
176.31 K
Short % Float
0.33%
-0.74%Week
-11.18%1 Month
-21.05%3 Month
-52.8%6 Month
-87.6%5 Year
-88.04%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
137.48 M
EPS (TTM)
-2.47
P/E Ratio
-
Ent. Value
139.99 M
Total Shares
101.84 M
Float Shares
81.29 M
Insiders
20.18%
Institutions
23.68%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NYXH Catalyst Timeline
Dated clinical, regulatory and corporate events for Nyxoah SA
Past FDA Catalysts and PDUFA Decisions
How NYXH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Nyxoah SA is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every NYXH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Genio Breakthrough | Complete Concentric Collapse (CCC) of the soft palate | 2026-09-02 | AHI responder rate: 77.2%; ODI responder rate: 87.7%; serious adverse events: zeroRead More | Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse PatientsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NYXH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 80.00 K | 47.36 K |
NYXH Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NYXH ranks across every disease it competes in
Competitive Position is a premium feature
See how NYXH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNYXH News
NYXH▼ -13.8%on this news
Nyxoah Nomme Liam Kelly au Poste de Chief Executive Officer
Nyxoah has appointed Liam Kelly as the new Chief Executive Officer, effective October 1, 2026, succeeding Olivier Taelman. This leadership change is part of Nyxoah's strategy to enhance its presence in the U.S. market following FDA approval and the launch of its Genio system. Kelly's extensive experience in the MedTech sector is expected to drive growth and value creation for the company.
Read more →NYXH▼ -13.8%on this news
Nyxoah Appoints Liam Kelly as Chief Executive Officer
Nyxoah has appointed Liam Kelly as the new Chief Executive Officer, effective October 1, 2026. This decision aligns with the company's strategy to enhance its presence in the U.S. market following FDA approval of its Genio system for Obstructive Sleep Apnea. Kelly brings over 25 years of leadership experience in the medical technology sector.
Read more →NYXH▼ -5.4%on this news
Nyxoah Announces Chief Financial Officer Transition
Nyxoah has announced a transition in its Chief Financial Officer position, with Loïc Moreau stepping in as interim CFO following John Landry's departure. The company reaffirms its financial guidance for 2026, expecting net revenue between €36 million and €40 million. Moreau's prior experience as CFO is expected to facilitate a smooth transition.
Read more →NYXHNyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System
Nyxoah has successfully implanted the first patient in the BREATHE study, a U.S. post-approval trial for its Genio® system aimed at treating obstructive sleep apnea. The study will involve up to 229 patients across 25 centers and will assess the therapy's long-term safety and effectiveness over five years. This marks a significant advancement in sleep medicine and neurostimulation therapy.
Read more →NYXH▲ +16.6%on this newsshared move
Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients
Nyxoah announced that its ACCCESS U.S. pivotal study for the Genio system met primary safety and efficacy endpoints for patients with Complete Concentric Collapse (CCC) of the soft palate. The study reported a 77.2% AHI responder rate and zero serious adverse events over 12 months. The company plans to submit a premarket approval supplement to the FDA to expand Genio's indication for CCC patients.
Read more →NYXH▼ -7.1%on this news
Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results
Nyxoah SA reported strong financial results for Q2 and the first half of 2026, with U.S. net revenue growing by 22% sequentially. The company secured €110 million in financing and achieved a 100% approval rate for prior authorization submissions. However, it also experienced an increase in operating losses and a decrease in gross margin due to a higher mix of U.S. revenue.
Read more →NYXHNyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026
Nyxoah SA announced it will release its financial results for Q2 2026 on August 5, 2026. A conference call will follow to discuss these results. The company, known for its innovative treatment for Obstructive Sleep Apnea, has seen recent successes including FDA approval and positive study outcomes. Investors can access the call via a webcast.
Read more →NYXHNyxoah Announces Preliminary Results for the Second Quarter of 2026
Nyxoah SA reported preliminary results for Q2 2026, highlighting a global net revenue of approximately €7.7 million, marking a 21% increase from the previous quarter. The U.S. revenue also showed strong growth at €5.2 million, with 55 new surgeons trained and 89 new accounts activated. Additionally, proposed reimbursement increases from CMS for the Genio procedure are expected to enhance economic value. The company secured $110 million in financing, positioning it for accelerated growth.
Read more →NYXHNyxoah Organisera une Journée Investisseurs à New York le 8 juillet 2026
Nyxoah SA will host an Investor Day on July 8, 2026, in New York, focusing on its business execution in the U.S. and growth strategy. The event will be held at Bank of America and will include discussions on the Genio system's market dynamics and reimbursement environment. A live webcast will be available for remote participants.
Read more →NYXHNyxoah to Host Investor Day in New York on July 8, 2026
Nyxoah SA will host an Investor and Analyst Day on July 8, 2026, in New York. The event will focus on the company's U.S. commercial execution, growth strategy, and key priorities, including the Genio system's market dynamics and reimbursement landscape. Participants will include Nyxoah's leadership and external clinical experts.
Read more →NYXHNyxoah Reçoit 15 Millions de Dollars de la Banque Européenne d’Investissement
Nyxoah SA has secured $15 million from the European Investment Bank, completing a total capital raise of $110 million. This funding will primarily support the commercial launch of its Genio system in the U.S. and further investments in R&D. The non-dilutive nature of the financing strengthens the company's balance sheet without affecting existing shareholders.
Read more →NYXHNyxoah Receives $15 Million from the European Investment Bank
Nyxoah has successfully drawn $15 million from the European Investment Bank, contributing to a total of $110 million raised in June 2026. This funding will primarily support the U.S. launch of their Genio system, a treatment for Obstructive Sleep Apnea. The non-dilutive nature of this financing enhances the company's financial position without affecting existing shareholders.
Read more →NYXHLa Thérapie Genio® de Nyxoah Remporte le Prix Galien UK 2026 de la Meilleure Technologie Médicale
Nyxoah SA's Genio® therapy for obstructive sleep apnea has won the Galien UK 2026 award for Best Medical Technology. This award is a significant recognition of the advancements made in treating obstructive sleep apnea, a condition affecting millions. The CEO emphasized the collective effort behind this success, which reflects the commitment to improving patient care. The company is also expanding its market presence following FDA approval.
Read more →NYXHNyxoah’s Genio® Wins Prix Galien UK 2026 Award for Best Medical Technology
Nyxoah's Genio® has been awarded the Prix Galien UK 2026 Award for Best Medical Technology, recognizing its innovative hypoglossal nerve stimulation therapy for Obstructive Sleep Apnea (OSA). This award underscores the technology's impact on patient care and the ongoing efforts of Nyxoah's team and healthcare partners. The company is also expanding its market presence following FDA approval and new financing.
Read more →NYXHInformation on the total number of voting rights and shares
Nyxoah SA has disclosed information regarding its total number of voting rights and shares following the issuance of 55,232,558 new shares. This issuance was part of an underwritten public offering in the United States, which included private offerings to institutional investors. The move demonstrates Nyxoah's strategy to enhance its capital base while engaging the investment community.
Read more →NYXHNyxoah Announces Closing of Underwritten Public Offering
Nyxoah SA has successfully closed an underwritten public offering, raising about $95 million through the sale of over 55 million shares at $1.72 each. The company plans to utilize the proceeds to expand its commercialization efforts in the U.S., enhance R&D for its Genio system, and support ongoing clinical research. This move is part of Nyxoah's strategy to strengthen its position in the Obstructive Sleep Apnea market.
Read more →NYXH▼ -49.7%on this newsshared move
Nyxoah Announces Pricing of $95 Million Underwritten Public Offering
Nyxoah SA has announced the pricing of a $95 million underwritten public offering, selling 55,232,558 ordinary shares at $1.72 each. The proceeds will be utilized for expanding commercialization efforts in the U.S., advancing R&D for the Genio system, and general corporate purposes. The offering is anticipated to close on June 9, 2026.
Read more →NYXHNyxoah Enters New Chapter of Long Term Value Creation
Nyxoah has announced a leadership transition to appoint a U.S.-based CEO, aiming to enhance its commercial efforts for the Genio system in the U.S. market. Olivier Taelman, the current CEO, will assist during the transition while the company seeks a new leader. This change is expected to support Nyxoah's growth in the expanding Obstructive Sleep Apnea market.
Read more →NYXHNyxoah Entre dans une Nouvelle Phase de Création de Valeur à Long Terme
Nyxoah is initiating a leadership transition to appoint a US-based CEO to accelerate its commercial launch of the Genio system in the US market. Olivier Taelman, the current CEO, will remain involved during the transition period. The company aims to leverage enhanced financial resources and a focused US leadership structure for its growth in the obstructive sleep apnea market.
Read more →NYXHNyxoah Announces Proposed Offering of Ordinary Shares
Nyxoah SA has announced a proposed underwritten public offering of ordinary shares in the U.S. to fund commercialization and R&D for its Genio system, aimed at treating Obstructive Sleep Apnea. The offering includes a potential 30-day option for underwriters to purchase additional shares. The company has received regulatory approvals for its innovative therapy, but the offering's completion is contingent on market conditions.
Read more →About Nyxoah SA
BIOPHARMAWATCH ELITE PLUS
Trade the next NYXH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime